What Phase 1, 2, and 3 mean
Compare trial phases and what they usually mean for safety, dosing, and evidence.
Phase 1 focuses on safety and dosing
Phase 1 studies usually test safety, side effects, dosing, and how a treatment behaves in the body.
They may enroll smaller groups (often a few dozen participants) and can involve more frequent monitoring than later-phase studies.
Because this is often the first time a treatment is tested in people, less is known about how it will work — the trade-off is closer supervision, not necessarily higher risk.
Phase 2 looks for activity
Phase 2 studies often ask whether a treatment appears to help a specific group of patients or condition.
They still monitor safety closely, but they usually provide more disease-specific evidence than Phase 1, typically with a larger group of participants (commonly dozens to a few hundred).
Phase 3 compares against standard care
Phase 3 studies are commonly larger — often hundreds to thousands of participants — and may compare a new treatment with standard care, placebo, or another accepted option.
These studies can be more structured, randomized, and important for regulatory decisions, meaning the results may directly influence whether a treatment becomes widely available.
Example:
A Phase 3 trial might randomly assign half of participants to a new drug and half to the current standard treatment, without either group choosing which one they get. This comparison is what makes the results reliable enough for approval decisions.
A quick note on Phase 4 and "N/A"
Some trials continue monitoring a treatment after approval — these are labeled Phase 4. Others, like most observational studies or trials of medical devices and procedures, don't test a drug dose at all, so phase doesn't apply to them.
Earlier phase generally means more unknowns
As a general pattern: earlier phases (1) usually involve more uncertainty about how well a treatment works, while later phases (3) usually involve more evidence — but also, in randomized studies, a chance you'll receive the standard treatment or a placebo instead of the new one. Neither is automatically the "better" choice — it depends on your situation and priorities, which is worth discussing with your clinician.
What to have ready
- The trial phase
- Whether treatment is randomized
- What the comparison group receives
- Visit schedule and monitoring
- Known risks and unknowns
Make this easier next time
Add your priorities to your medical card, and we'll highlight the phase and design details that matter most for your situation when you're comparing trials.
